Skip to content

Study · Not a test of the peptide alone · 2018

1 result

Interferon-gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells.

Wang QS, Shen SQ, Sun HW, Xing ZX, Yang HL

Biochemical and biophysical research communications19 Mar 2018Cited by 33 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In SW480 and HCT116 colorectal cancer cells, the mitochondria-targeted antioxidant SS31 and/or the cPLA2 inhibitor AACOCF3 abolished the ROS production, autophagy and apoptosis induced by IFN-γ.

    In plain wordsIn colorectal cancer cells, SS31 and/or a cPLA2 inhibitor blocked the ROS, autophagy and cell death that interferon-gamma caused.

    Outcome
    Not applicableIFN-γ-induced ROS production, autophagy and apoptosis
    Study

    n: not reported in source

    SW480 and HCT116 colorectal cancer cell lines
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In addition, a mitochondria-targeted antioxidant SS31 and/or cPLA2 inhibitor AACOCF3 abolished the IFN-γ-induced ROS production and subsequent autophagy and apoptosis.
    1 context sentence
    Summary · context
    We observed that IFN-γ induced mitochondria-derived reactive oxygen species (ROS) production in a time-dependent manner in SW480 and HCT116 cell lines.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.